down arrow

Guanhao Biotech Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100001575
CNY
14.62
-0.37 (-2.47%)

Dec 04

SHE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Guanhao Biotech Co., Ltd.
Why is Guanhao Biotech Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 4.90%
  • The company has been able to generate a Return on Capital Employed (avg) of 4.90% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -2.34% and Operating profit at 17.05% over the last 5 years
3
Negative results in Mar 25
  • OPERATING CASH FLOW(Y) Lowest at CNY 53.75 MM
  • DEBT-EQUITY RATIO (HY) Highest at 1.47 %
  • INTEREST(Q) Highest at CNY 1.02 MM
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Guanhao Biotech Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Guanhao Biotech Co., Ltd.
7.9%
1.48
51.23%
China Shanghai Composite
14.77%
1.01
15.10%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-2.34%
EBIT Growth (5y)
17.05%
EBIT to Interest (avg)
-9.65
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
0.62
Tax Ratio
39.74%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.90%
ROE (avg)
3.69%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
226
Industry P/E
Price to Book Value
6.55
EV to EBIT
191.39
EV to EBITDA
76.87
EV to Capital Employed
6.72
EV to Sales
9.64
PEG Ratio
1.98
Dividend Yield
NA
ROCE (Latest)
3.51%
ROE (Latest)
2.89%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

17What is working for the Company
ROCE(HY)

Highest at 5.11%

PRE-TAX PROFIT(Q)

At CNY 19.23 MM has Grown at 169.63%

RAW MATERIAL COST(Y)

Fallen by -4.21% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 5.03%

NET PROFIT(Q)

Highest at CNY 14.87 MM

EPS(Q)

Highest at CNY 0.06

-14What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at CNY 53.75 MM

DEBT-EQUITY RATIO (HY)

Highest at 1.47 %

INTEREST(Q)

Highest at CNY 1.02 MM

Here's what is working for Guanhao Biotech Co., Ltd.
Pre-Tax Profit
At CNY 19.23 MM has Grown at 169.63%
over average net sales of the previous four periods of CNY 7.13 MM
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit
At CNY 14.87 MM has Grown at 116.89%
over average net sales of the previous four periods of CNY 6.85 MM
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (CNY MM)

Net Profit
Highest at CNY 14.87 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS
Highest at CNY 0.06
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Debtors Turnover Ratio
Highest at 5.03%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -4.21% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Guanhao Biotech Co., Ltd.
Interest
At CNY 1.02 MM has Grown at 79.29%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Operating Cash Flow
Lowest at CNY 53.75 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Interest
Highest at CNY 1.02 MM
in the last five periods and Increased by 79.29% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio
Highest at 1.47 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."